Jazz Pharmaceuticals plc (NASDAQ:JAZZ) management will conduct a conference call for 2nd November 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.jazzpharma.com
Earnings Expectation
Jazz Pharmaceuticals plc is reporting third quarter financial results on Monday 2nd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, JAZZ is expected to report 3Q20 income of $ 4.08 per share from revenue of $ 577.58 million.
For the full year, analysts anticipate top line of $ 2281.35 million, while looking forward to income of $ 12.47 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 2,225.00 million ~ $ 2,325.00 million, where as bottomline are predicted in a range of $ 11.90 ~ $ 13.00 per share
Click Here For More Historical Outlooks Of Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia.
